The stock has a 36-month beta value of 1.26. Opinions on the stock are mixed, with 5 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ANNX is 95.53M, and at present, short sellers hold a 10.60% of that float. On June 05, 2025, the average trading volume of ANNX was 1.74M shares.
ANNX) stock’s latest price update
The stock price of Annexon Inc (NASDAQ: ANNX) has surged by 5.65 when compared to previous closing price of 2.30, but the company has seen a 19.70% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-05-29 that BRISBANE, Calif., May 29, 2025 (GLOBE NEWSWIRE) — Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that Douglas Love, president and chief executive officer, will present at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 8:10 a.m. EST.
ANNX’s Market Performance
ANNX’s stock has risen by 19.70% in the past week, with a monthly rise of 34.25% and a quarterly drop of -11.96%. The volatility ratio for the week is 6.48% while the volatility levels for the last 30 days are 5.30% for Annexon Inc The simple moving average for the last 20 days is 23.07% for ANNX stock, with a simple moving average of -44.05% for the last 200 days.
Analysts’ Opinion of ANNX
Many brokerage firms have already submitted their reports for ANNX stocks, with JP Morgan repeating the rating for ANNX by listing it as a “Overweight.” The predicted price for ANNX in the upcoming period, according to JP Morgan is $11 based on the research report published on March 01, 2024 of the previous year 2024.
BofA Securities, on the other hand, stated in their research note that they expect to see ANNX reach a price target of $6, previously predicting the price at $4. The rating they have provided for ANNX stocks is “Buy” according to the report published on December 21st, 2023.
Wells Fargo gave a rating of “Overweight” to ANNX, setting the target price at $11 in the report published on October 30th of the previous year.
ANNX Trading at 30.12% from the 50-Day Moving Average
After a stumble in the market that brought ANNX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -69.04% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at ANNX starting from Dananberg Jamie, who sale 5,521 shares at the price of $2.96 back on Feb 18 ’25. After this action, Dananberg Jamie now owns 33,479 shares of Annexon Inc, valued at $16,342 using the latest closing price.
ARTIS DEAN RICHARD, the EVP & CHIEF SCIENTIFIC OFFICER of Annexon Inc, sale 5,515 shares at $2.97 during a trade that took place back on Feb 18 ’25, which means that ARTIS DEAN RICHARD is holding 83,814 shares at $16,380 based on the most recent closing price.
Stock Fundamentals for ANNX
The total capital return value is set at -0.68. Equity return is now at value -66.13, with -55.14 for asset returns.
Based on Annexon Inc (ANNX), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at -4.94.
Currently, EBITDA for the company is -134.75 million with net debt to EBITDA at 0.38. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.99.
Conclusion
To sum up, Annexon Inc (ANNX) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
